Business Context and Reporting Period
DNA X, Inc. (Nasdaq: SONM), a Delaware corporation, filed this Form 8-K on August 21, 2026. The report addresses a specific corporate governance event regarding director compensation rather than routine financial operations.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The only financial figure disclosed is the valuation assumption for a compensation grant:
- Compensation Grant Value: $60,000 per director (based on the fair market value of common stock on August 21, 2026).
Material Changes
The material change reported is the substitution of equity-based compensation with cash awards for all Board members, including CEO Mike Mulica. This change was necessitated by the unavailability of shares under the Company's 2019 Equity Incentive Plan (EIP).
Outlook, Management Commentary, and Risks
Compensation Methodology: The Board approved "Substitute Cash Grants" designed to replicate the vesting of Restricted Stock Units (RSUs). The grants are treated as "Phantom RSUs" valued at $60,000 each.
Vesting Conditions: The cash awards will vest and become payable upon the earlier of:
- The Company's 2027 annual meeting of stockholders.
- A change in control of the Company.
Payment Terms: The payout amount will equal the fair market value of the underlying stock at the time of the Vesting Event, not the initial $60,000 valuation.
Investor Verification Checklist
- Verify the current share availability status under the 2019 Equity Incentive Plan to understand the scope of the cash substitution.
- Monitor the Company's stock price trajectory, as the final cash payout to directors is variable and tied to the stock price at the 2027 annual meeting or a change in control.
- Review upcoming filings for any updates on the 2027 annual meeting schedule or potential change in control events.